Literature DB >> 22789772

[Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder].

Antoni Sicras-Mainar1, Jorge Mauriño, Luis Cordero, Milagrosa Blanca-Tamayo, Ruth Navarro-Artieda.   

Abstract

OBJECTIVE: To evaluate the compliance, persistence and costs of the treatment of major depressive disorder (MDD) in the setting of Primary Care, placing emphasis on the different aspects of those patients with an initial suboptimal response to antidepressant treatment.
DESIGN: A retrospective observational study using the population registers of Badalona Healthcare Services. The inclusion criteria consisted of; age ≥18 years, initial episode during 2008-2009, and to be on antidepressant treatment for at least 8 weeks after the first prescription. The follow-up was 12 months. Two study groups were formed, patients with suboptimal response, and remission. MAIN MEASUREMENTS: Sociodemographic data, compliance and adherence to treatment, health costs (direct and indirect).
RESULTS: A total of 2,260 subjects were analysed (mean age 58.8 years, 74% women). Just under half (42.7%, 95% CI; 40.0-46.4%) had a suboptimal response to the treatment. These patients had a higher mean age, a higher proportion of women, and pensioners, as well as higher comorbidity, compared to the remission group. They also had poorer compliance percentages (65.1% vs. 67.7%) and treatment persistence at 12 months (31.8% vs. 53.2%), respectively, P<.001. The annual health costs were, 826.1€ for patients with a suboptimal response vs. 451.2€ in patients in remission; loss of productivity 1,842.0€ vs. 991.4€, respectively; P<.001. The factors associated to a suboptimal response were; lack of compliance (OR=1.7), years with the disorder (OR=1.2), age (OR=1.1) and presence of comorbidity (OR=1.1).
CONCLUSIONS: The patients with an initial suboptimal response to antidepressant treatment had a higher comorbidity, lower therapeutic compliance, and incurred higher total costs, particularly in losses in work productivity.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789772      PMCID: PMC7025939          DOI: 10.1016/j.aprim.2012.04.007

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  31 in total

1.  [Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study].

Authors:  Josep M Haro; Concepció Palacín; Gemma Vilagut; Montse Martínez; Mariola Bernal; Inma Luque; Miquel Codony; Montse Dolz; Jordi Alonso
Journal:  Med Clin (Barc)       Date:  2006-04-01       Impact factor: 1.725

2.  Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond.

Authors:  Martin B Keller
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

Review 3.  The keys to improving depression outcomes.

Authors:  Sakina J Rizvi; Sidney H Kennedy
Journal:  Eur Neuropsychopharmacol       Date:  2011-09       Impact factor: 4.600

4.  Randomised clinical trial of strategies for improving medication compliance in primary hypertension.

Authors:  D L Sackett; R B Haynes; E S Gibson; B C Hackett; D W Taylor; R S Roberts; A L Johnson
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

Review 5.  The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.

Authors:  Mark Sinyor; Ayal Schaffer; Anthony Levitt
Journal:  Can J Psychiatry       Date:  2010-03       Impact factor: 4.356

Review 6.  If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.

Authors:  K Ryan Connolly; Michael E Thase
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

7.  Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

Authors:  Rudolf Uher; Ole Mors; Marcella Rietschel; Aleksandra Rajewska-Rager; Ana Petrovic; Astrid Zobel; Neven Henigsberg; Julien Mendlewicz; Katherine J Aitchison; Anne Farmer; Peter McGuffin
Journal:  J Clin Psychiatry       Date:  2011-11       Impact factor: 4.384

8.  The burden of mental disorders in primary care.

Authors:  G Grandes; I Montoya; M S Arietaleanizbeaskoa; V Arce; A Sanchez
Journal:  Eur Psychiatry       Date:  2011-02-08       Impact factor: 5.361

9.  The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.

Authors:  P Sobocki; M Ekman; H Agren; B Runeson; B Jönsson
Journal:  Int J Clin Pract       Date:  2006-07       Impact factor: 2.503

Review 10.  Review: the net benefits of depression management in primary care.

Authors:  Sherry Glied; Karin Herzog; Richard Frank
Journal:  Med Care Res Rev       Date:  2010-01-21       Impact factor: 3.929

View more
  1 in total

Review 1.  Cost of disorders of the brain in Spain.

Authors:  Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.